Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-670-7370
Oncolytics Biotech Inc.

In Vivo Synergy Between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HTC-116 Xenografts

Caption: Poster by Dr. Maureen E. Lane et al. of Cornell University, N.Y., titled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts." Dr. Lane and her team found that treatment of human colon cancer cell lines with the combination of Reolysin and gemcitabine resulted in both in vitro and in vivo synergy. There was no toxicity associated with the combined treatment. Tumors treated with the combination were significantly smaller (by area and weight) than tumors in control groups or tumors treated with either agent alone. The researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials. Dr. Lane presented her findings at the American Association for Cancer Research Annual Meeting in Los Angeles, Calif. The meeting runs from April 14-18, 2007.

Credit: Dr. Maureen E. Lane and Oncolytics Biotech

Usage Restrictions: None

Related news release: Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine